{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,28]],"date-time":"2026-10-28T23:26:18Z","timestamp":1793229978048,"version":"4.5.0"},"reference-count":49,"publisher":"American Medical Association (AMA)","issue":"5","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["JAMA Netw Open"],"abstract":"\n Importance<\/jats:title>\n Treatments are urgently needed for the more than 9500 rare diseases with no US Food and Drug Administration\u2013approved therapies. Although repurposing can be less time- and cost-intensive compared with novel drug development, hurdles have impeded systematic repurposing. Rare disease nonprofit organizations (RDNPs) are well-positioned to overcome barriers and have spearheaded rare disease repurposing efforts for decades. However, no comprehensive data are available on the state of rare disease repurposing or features of successful efforts.<\/jats:p>\n <\/jats:sec>\n \n Objective<\/jats:title>\n To characterize the state of rare disease drug repurposing, identify factors associated with successful outcomes, and share thematic insights using the interactive Repurposing of All Drugs, Mapping All Paths (ROADMAP) Project web tool.<\/jats:p>\n <\/jats:sec>\n \n Design, Setting, and Participants<\/jats:title>\n The ROADMAP study was a qualitative study using a mixed-methods analysis of US-based RDNP leaders and their stakeholders, including a national survey and semistructured interviews of RDNP leaders, conducted from September 29, 2021, to January 6, 2022. Surveys and interviews revealed themes associated with RDNP strategies, timelines, and support mechanisms. Data were analyzed from January 22, 2024, to April 23, 2024.<\/jats:p>\n <\/jats:sec>\n \n Main Outcomes and Measures<\/jats:title>\n \n The primary survey outcome was the repurposing project stage (abandoned, early, clinical, late, or successful). Qualitative outcomes included themes characterizing repurposing experiences. Two random forest models of drug- and disease- specific as well as organization-specific variables were used to evaluate factor importance toward inferring the project stage. Orthogonal significance testing was conducted using Spearman rank correlation, and\n P<\/jats:italic>\n values in each model were corrected for multiple hypothesis testing using a Benjamini-Hochberg procedure.\n <\/jats:p>\n <\/jats:sec>\n \n Results<\/jats:title>\n \n Representative organizations submitted survey responses, including 147 of 698 potential US-based RDNPs. The median RDNP age was 10 years (IQR, 5-20 years), and the median annual revenue was $355\u202f390 (IQR, $90\u202f028-$946\u202f108). Among 34 leaders who were interviewed, representing 25 RDNPs, 23 were female (67.6%), and the RDNPs had a median age of 15 years (IQR, 6-19 years) and a median revenue of $670\u202f719 (IQR, $193\u202f587-$1\u202f830\u202f890). Among the surveyed RDNPs, 58 of 138 (42.0%) specifically identifying their involvement in repurposing supported repurposing projects, and 94 drugs were in various stages of repurposing, of which 23 met success criteria (5 with US Food and Drug Administration approval and 18 with off-label use with subjective benefit). Survey factors associated with successful outcomes included nonprofit-supported patient recruitment into trials (Gini importance, 3.90; \u03c1 = 0.50; adjusted\n P<\/jats:italic>\n \u2009&amp;lt;\u2009.001) and provision of nonfinancial research support (Gini importance, 0.69; \u03c1 = 0.33; adjusted\n P<\/jats:italic>\n \u2009=\u2009.02). Interview themes were synthesized into a 5-stage repurposing framework with roadblocks and recommendations that included (1) enabling drug repurposing, (2) identifying a drug therapy, (3) validating a drug therapy, (4) clinical use and testing, and (5) reaching an optimal end point for clinical practice.\n <\/jats:p>\n <\/jats:sec>\n \n Conclusions and Relevance<\/jats:title>\n The findings of this qualitative study of RDNP repurposing suggest that several opportunities were associated with successful outcomes and can be considered to optimize systematic repurposing among RDNPs, external collaborators, and policymakers with the use of an interactive tool showcasing insights to facilitate data-driven drug repurposing.<\/jats:p>\n <\/jats:sec>","DOI":"10.1001\/jamanetworkopen.2025.8330","type":"journal-article","created":{"date-parts":[[2025,5,5]],"date-time":"2025-05-05T11:00:28Z","timestamp":1746442828000},"page":"e258330","source":"Crossref","is-referenced-by-count":12,"title":["Rare Disease Drug Repurposing"],"prefix":"10.1001","volume":"8","author":[{"given":"Sally","family":"Nijim","sequence":"first","affiliation":[{"name":"Castleman Disease Collaborative Network, Paso Robles, California"},{"name":"Center for Cytokine Storm Treatment and Laboratory, University of Pennsylvania Perelman School of Medicine, Philadelphia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ania","family":"Korsunska","sequence":"additional","affiliation":[{"name":"Castleman Disease Collaborative Network, Paso Robles, California"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Joseph","family":"Zinski","sequence":"additional","affiliation":[{"name":"Center for Cytokine Storm Treatment and Laboratory, University of Pennsylvania Perelman School of Medicine, Philadelphia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sarah E.","family":"Bolden","sequence":"additional","affiliation":[{"name":"School of Information Studies, Syracuse University, Syracuse, New York"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mary","family":"Zuccato","sequence":"additional","affiliation":[{"name":"Castleman Disease Collaborative Network, Paso Robles, California"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mileva","family":"Repasky","sequence":"additional","affiliation":[{"name":"Castleman Disease Collaborative Network, Paso Robles, California"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David C.","family":"Fajgenbaum","sequence":"additional","affiliation":[{"name":"Castleman Disease Collaborative Network, Paso Robles, California"},{"name":"Center for Cytokine Storm Treatment and Laboratory, University of Pennsylvania Perelman School of Medicine, Philadelphia"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"10","published-online":{"date-parts":[[2025,5,5]]},"reference":[{"issue":"2","key":"zoi250303r1","doi-asserted-by":"publisher","first-page":"77","DOI":"10.1038\/d41573-019-00180-y","article-title":"How many rare diseases are there?","volume":"19","author":"Haendel","year":"2020","journal-title":"Nat Rev Drug Discov"},{"issue":"1","key":"zoi250303r3","doi-asserted-by":"publisher","first-page":"163","DOI":"10.1186\/s13023-023-02790-7","article-title":"A comprehensive study of the rare diseases and conditions targeted by orphan drug designations and approvals over the forty years of the Orphan Drug Act.","volume":"18","author":"Fermaglich","year":"2023","journal-title":"Orphanet J Rare Dis"},{"issue":"1","key":"zoi250303r4","doi-asserted-by":"publisher","first-page":"41","DOI":"10.1038\/nrd.2018.168","article-title":"Drug repurposing: progress, challenges and recommendations.","volume":"18","author":"Pushpakom","year":"2019","journal-title":"Nat Rev Drug Discov"},{"issue":"5","key":"zoi250303r5","doi-asserted-by":"publisher","first-page":"703","DOI":"10.1038\/s41416-023-02502-9","article-title":"Unlocking hidden potential: advancements, approaches, and obstacles in repurposing drugs for cancer therapy.","volume":"130","author":"Weth","year":"2024","journal-title":"Br J Cancer"},{"issue":"7","key":"zoi250303r6","doi-asserted-by":"publisher","first-page":"1785","DOI":"10.1016\/j.drudis.2022.05.026","article-title":"Drug repurposing: an effective strategy to accelerate contemporary drug discovery.","volume":"27","author":"Zhan","year":"2022","journal-title":"Drug Discov Today"},{"issue":"12","key":"zoi250303r7","doi-asserted-by":"publisher","first-page":"1147","DOI":"10.1056\/NEJMc2108482","article-title":"Interleukin-6 receptor antagonists in critically ill patients with Covid-19.","volume":"385","author":"Brown","year":"2021","journal-title":"N Engl J Med"},{"issue":"2","key":"zoi250303r8","doi-asserted-by":"publisher","first-page":"302","DOI":"10.1080\/14397595.2018.1532383","article-title":"A benefit and the prospects of IL-6 inhibitors in idiopathic multicentric Castleman\u2019s disease.","volume":"29","author":"Koga","year":"2019","journal-title":"Mod Rheumatol"},{"issue":"2","key":"zoi250303r9","doi-asserted-by":"publisher","first-page":"258","DOI":"10.1080\/14397595.2018.1546357","article-title":"IL-6 inhibitor for the treatment of rheumatoid arthritis: a comprehensive review.","volume":"29","author":"Ogata","year":"2019","journal-title":"Mod Rheumatol"},{"issue":"1","key":"zoi250303r10","doi-asserted-by":"publisher","first-page":"18","DOI":"10.1186\/s40360-017-0128-7","article-title":"Large-scale detection of drug off-targets: hypotheses for drug repurposing and understanding side-effects.","volume":"18","author":"Chartier","year":"2017","journal-title":"BMC Pharmacol Toxicol"},{"issue":"10","key":"zoi250303r11","doi-asserted-by":"publisher","first-page":"3835","DOI":"10.1111\/bcp.14792","article-title":"Repurposing of thalidomide and its derivatives for the treatment of SARS-CoV-2 infections: hints on molecular action.","volume":"87","author":"Sundaresan","year":"2021","journal-title":"Br J Clin Pharmacol"},{"issue":"6","key":"zoi250303r12","doi-asserted-by":"publisher","first-page":"831","DOI":"10.1007\/s40258-023-00816-6","article-title":"Drug repurposing of generic drugs: challenges and the potential role for government.","volume":"21","author":"van der Pol","year":"2023","journal-title":"Appl Health Econ Health Policy"},{"issue":"6","key":"zoi250303r13","doi-asserted-by":"publisher","first-page":"62","DOI":"10.1007\/s11886-021-01484-5","article-title":"Drug repurposing: claiming the full benefit from drug development.","volume":"23","author":"Kort","year":"2021","journal-title":"Curr Cardiol Rep"},{"issue":"3","key":"zoi250303r14","doi-asserted-by":"publisher","first-page":"323","DOI":"10.1592\/phco.26.3.323","article-title":"The major role of clinicians in the discovery of off-label drug therapies.","volume":"26","author":"Demonaco","year":"2006","journal-title":"Pharmacotherapy"},{"issue":"10","key":"zoi250303r16","doi-asserted-by":"publisher","first-page":"982","DOI":"10.1016\/j.mayocp.2012.04.017","article-title":"Ten common questions (and their answers) about off-label drug use.","volume":"87","author":"Wittich","year":"2012","journal-title":"Mayo Clin Proc"},{"issue":"9","key":"zoi250303r17","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0204427","article-title":"Use of off-label and unlicensed medicines in neonatal intensive care.","volume":"13","author":"Costa","year":"2018","journal-title":"PLoS One"},{"issue":"4","key":"zoi250303r18","doi-asserted-by":"publisher","first-page":"397","DOI":"10.1080\/17460441.2020.1704729","article-title":"Challenges and opportunities with drug repurposing: finding strategies to find alternative uses of therapeutics.","volume":"15","author":"Talevi","year":"2020","journal-title":"Expert Opin Drug Discov"},{"issue":"1","key":"zoi250303r19","doi-asserted-by":"publisher","first-page":"970","DOI":"10.1186\/s12913-022-08272-z","article-title":"Drug repurposing: a systematic review on root causes, barriers and facilitators.","volume":"22","author":"Krishnamurthy","year":"2022","journal-title":"BMC Health Serv Res"},{"issue":"612","key":"zoi250303r20","doi-asserted-by":"publisher","DOI":"10.1126\/scitranslmed.abd5524","article-title":"Drug repurposing: misconceptions, challenges, and opportunities for academic researchers.","volume":"13","author":"Begley","year":"2021","journal-title":"Sci Transl Med"},{"issue":"1","key":"zoi250303r21","doi-asserted-by":"publisher","first-page":"3","DOI":"10.1186\/s40545-020-00282-8","article-title":"Repurposing existing drugs for new uses: a cohort study of the frequency of FDA-granted new indication exclusivities since 1997.","volume":"14","author":"Sahragardjoonegani","year":"2021","journal-title":"J Pharm Policy Pract"},{"issue":"8","key":"zoi250303r22","doi-asserted-by":"publisher","first-page":"1027","DOI":"10.1016\/j.drudis.2015.05.001","article-title":"Drug repositioning and repurposing: terminology and definitions in literature.","volume":"20","author":"Langedijk","year":"2015","journal-title":"Drug Discov Today"},{"issue":"6","key":"zoi250303r23","doi-asserted-by":"publisher","first-page":"507","DOI":"10.1007\/s10928-023-09859-7","article-title":"The future of rare disease drug development: the rare disease cures accelerator data analytics platform (RDCA-DAP).","volume":"50","author":"Barrett","year":"2023","journal-title":"J Pharmacokinet Pharmacodyn"},{"issue":"7","key":"zoi250303r24","doi-asserted-by":"publisher","first-page":"1595","DOI":"10.1111\/bcp.13240","article-title":"Affordable orphan drugs: a role for not-for-profit organizations.","volume":"83","author":"Davies","year":"2017","journal-title":"Br J Clin Pharmacol"},{"key":"zoi250303r25","doi-asserted-by":"publisher","DOI":"10.3389\/fphar.2021.746987","article-title":"Drug repurposing for rare diseases: a role for academia.","volume":"12","author":"van den Berg","year":"2021","journal-title":"Front Pharmacol"},{"issue":"2","key":"zoi250303r26","doi-asserted-by":"publisher","first-page":"286","DOI":"10.1377\/hlthaff.2014.1038","article-title":"The roles of academia, rare diseases, and repurposing in the development of the most transformative drugs.","volume":"34","author":"Kesselheim","year":"2015","journal-title":"Health Aff (Millwood)"},{"issue":"4","key":"zoi250303r34","doi-asserted-by":"publisher","first-page":"1195","DOI":"10.1111\/1475-6773.12275","article-title":"Using grounded theory method to capture and analyze health care experiences.","volume":"50","author":"Foley","year":"2015","journal-title":"Health Serv Res"},{"issue":"2","key":"zoi250303r36","doi-asserted-by":"publisher","first-page":"162","DOI":"10.1038\/ejhg.2016.137","article-title":"IRDiRC recognized resources\u201d: a new mechanism to support scientists to conduct efficient, high-quality research for rare diseases.","volume":"25","author":"Lochm\u00fcller","year":"2017","journal-title":"Eur J Hum Genet"},{"issue":"1","key":"zoi250303r43","doi-asserted-by":"publisher","first-page":"229","DOI":"10.1186\/s13023-023-02845-9","article-title":"How to START? four pillars to optimally begin your orphan drug development.","volume":"18","author":"Jonker","year":"2023","journal-title":"Orphanet J Rare Dis"},{"key":"zoi250303r46","doi-asserted-by":"publisher","DOI":"10.3389\/fmed.2024.1352803","article-title":"Drug repurposing for rare: progress and opportunities for the rare disease community.","volume":"11","author":"Jonker","year":"2024","journal-title":"Front Med (Lausanne)"},{"issue":"1","key":"zoi250303r47","doi-asserted-by":"publisher","first-page":"75","DOI":"10.1186\/s13023-023-02678-6","article-title":"A model for crowdsourcing high-impact research questions for Castleman disease and other rare diseases.","volume":"18","author":"Korsunska","year":"2023","journal-title":"Orphanet J Rare Dis"},{"issue":"9","key":"zoi250303r48","doi-asserted-by":"publisher","first-page":"562","DOI":"10.1038\/gt.2017.29","article-title":"The importance of international collaboration for rare diseases research: a European perspective.","volume":"24","author":"Julkowska","year":"2017","journal-title":"Gene Ther"},{"issue":"9","key":"zoi250303r49","doi-asserted-by":"publisher","DOI":"10.20517\/rdodj.2023.04","article-title":"Sustainable approaches for drug repurposing in rare diseases: recommendations from the IRDiRC Task Force.","volume":"2","author":"Zanello","year":"2023","journal-title":"Rare Dis Orphan Drugs J"},{"key":"zoi250303r2","unstructured":"Orphan Drug Act of 1983. HR 5238, 97th Congress (1981-1983). Accessed January 15, 2025. https:\/\/www.fda.gov\/media\/99546\/download"},{"key":"zoi250303r15","unstructured":"FDA drug topics: CURE ID: capturing clinician\u2019s experiences repurposing drugs to inform future studies in the era of COVID-19\u2014June 9, 2020. US Food and Drug Administration. June 9, 2020. Accessed March 23, 2024. https:\/\/www.fda.gov\/about-fda\/fda-pharmacy-student-experiential-program\/fda-drug-topics-cure-id-capturing-clinicians-experiences-repurposing-drugs-inform-future-studies-era"},{"key":"zoi250303r27","unstructured":"Repurposing of All Drugs, Mapping All Paths (ROADMAP). Castleman Disease Collaborative Network. Accessed March 23, 2024. https:\/\/everycure.github.io\/"},{"key":"zoi250303r28","unstructured":"GuideStar Pro. Candid. Accessed April 14, 2024. https:\/\/www.guidestar.org\/guidestar-pro"},{"key":"zoi250303r29","unstructured":"Global Genes. Accessed January 21, 2025. https:\/\/globalgenes.org"},{"key":"zoi250303r30","unstructured":"National Organization for Rare Disorders. Accessed January 21, 2025. https:\/\/rarediseases.org"},{"key":"zoi250303r31","unstructured":"Rare As One Project. Chan Zuckerberg Initiative. Accessed January 21, 2025. https:\/\/chanzuckerberg.com\/science\/programs-resources\/rare-as-one\/"},{"key":"zoi250303r32","unstructured":"Drugs@FDA: FDA-approved drugs. US Food and Drug Administration. Accessed January 21, 2025. https:\/\/www.accessdata.fda.gov\/scripts\/cder\/daf\/index.cfm"},{"key":"zoi250303r33","unstructured":"Otter.ai. Accessed March 23, 2024. https:\/\/otter.ai\/"},{"key":"zoi250303r35","unstructured":"Dedoose. Version 9.0.107. SocioCultural Research Consultants; 2018. Accessed November 1, 2022. https:\/\/www.dedoose.com\/"},{"key":"zoi250303r37","unstructured":"European infrastructure for translational medicine. Eatris Eric. Accessed January 21, 2025. https:\/\/eatris.eu\/"},{"key":"zoi250303r38","unstructured":"Reshaping drug repurposing. Repurposing of Medicines 4 All (REMEDi4ALL). Accessed January 21, 2025. https:\/\/remedi4all.org"},{"key":"zoi250303r39","unstructured":"The Euro-global platform for mechanism-based drug repurposing. RePo4EU. Accessed January 21, 2025. https:\/\/repo4.eu"},{"key":"zoi250303r40","unstructured":"Critical Path Institute. Accessed January 21, 2025. https:\/\/c-path.org"},{"key":"zoi250303r41","unstructured":"NCATS toolkit for patient-focused therapy development. National Center for Advancing Translational Sciences. Accessed January 21, 2025. https:\/\/ncats.nih.gov\/research\/research-resources\/ncats-toolkit"},{"key":"zoi250303r42","unstructured":"The Orphan Drug Development Guidebook (ODDG). International Rare Diseases Research Consortium (IRDiRC). Accessed January 21, 2025. https:\/\/orphandrugguide.org\/home"},{"key":"zoi250303r44","unstructured":"CREATE bio example: target product profile (TPP). National Institute of Neurological Disorders and Stroke. Accessed January 21, 2025. https:\/\/www.ninds.nih.gov\/current-research\/research-funded-ninds\/translational-research\/create-bio\/create-bio-application-support-library\/create-bio-example-target-product-profile-tpp"},{"key":"zoi250303r45","unstructured":"The Target Development Profile Toolkit. Gov.UK. Government of the United Kingdom. Accessed January 21, 2025. https:\/\/www.gov.uk\/guidance\/the-target-development-profile-toolkit"}],"container-title":["JAMA Network Open"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/jamanetwork.com\/journals\/jamanetworkopen\/articlepdf\/2833518\/nijim_2025_oi_250303_1745610423.50494.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,5,5]],"date-time":"2025-05-05T11:00:36Z","timestamp":1746442836000},"score":1,"resource":{"primary":{"URL":"https:\/\/jamanetwork.com\/journals\/jamanetworkopen\/fullarticle\/2833518"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,5,5]]},"references-count":49,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2025,5,1]]}},"URL":"https:\/\/doi.org\/10.1001\/jamanetworkopen.2025.8330","relation":{},"ISSN":["2574-3805"],"issn-type":[{"value":"2574-3805","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,5,5]]}}}